Kazakhstan's domestically produced cancer drug enters second phase of clinical trials

Kazakhstan's domestically produced cancer drug is facing delays due to stringent clinical trial requirements. The first phase has concluded successfully, and the second phase is commencing. The Ministry of Science and Higher Education anticipates completing development and beginning market introduction by mid-next year. Initial development began in January 2024.

Read the full article at Informburo →

Headline and summary written by daryo. The full report belongs to Informburo.